$0
Kymriah’s First Commercial Manufacturing Facility Approved in Australia; Novartis Increases Manufacturing Footprint to Six Global Centers
On Friday, February 12, Novartis announced (press release) that the Peter MacCallum Cancer Center in Melbourne has been approved by the Therapeutic Goods Administration (TGA) to commercially manufacture Kymriah. Below, Celltelligence provides thoughts on the impact of Novartis’s manufacturing footprint strategy and anticipated manufacturing approval in China.